Nooman is Managing Director of Life Sciences & Digital Health at Silicon Valley Bank UK, the only bank in the UK focused solely on the innovation economy. Nooman leads a team dedicated to supporting early, growth stage and established businesses across all sectors of life sciences.
Andrew has over 30 years’ experience in finance and has helped Biotech companies raise in excess of $400m of equity in recent years. The companies include Artios Pharma, Bicycle Therapeutics, Kymab, Mission Therapeutics and PhoreMost. Andrew co-founded Acacia Pharma and served as CEO of Amura Therapeutics. He is currently Chief Financial Officer at Artios Pharma.
Bailey Fisher is pleased to be partnering again with Silicon Valley Bank and Taylor Wessing to present the latest in our series of Life Sciences Dinners. The event offers the opportunity for business leaders from the sector to meet for an informal dinner and discussion. The topic for the evening is ‘Accelerators: fast track to success’ and we will be joined by a group of experts who will play a part in discussion around the table, including Jason Mellad, Co-founder & CEO of Start Codon, a new Cambridge accelerator focusing on the most exciting pre-Series A life science and healthtech companies globally.
Ian has 25+ years’ experience in life sciences, from academic research to biotech start-up to big pharma. He founded Domantis with Sir Gregory Winter, acquired by GSK for $454m and was SVP, Head of Worldwide Business Development & Head of Biopharm R&D at GSK. Currently Chairman of Stevenage Bioscience Catalyst, the UK’s first open innovation biomedical campus; chair of the Investment Committee for Apollo Therapeutics, a £40m fund dedicated to turning academic biotechnologies into novel medicines.
Shaun has global responsibility for Strategic Partnering & Business Development, dedicated to broadening AstraZeneca’s access to scientific innovation outside its own labs. His background includes ICI, Zeneca, and AstraZeneca in Corporate, Pharmaceuticals & US Legal departments, HR & Business Development. Major projects include the AstraZeneca merger, creation of Avecia & Syngenta, acquisition of Cambridge Antibody Technology, MedImmune & Amylin, and the spin out of Albireo.
In a 40+ year career, during which he has served with 4 of the top 10 pharma companies, David was named as co-inventor on the patent for Viagra and played a pivotal role in the discovery of Relpax, a treatment for Migraine. More recently, he has co-founded companies including Crescendo Biologics and Healx. An active angel investor, David chairs the board of Healx, ProFactor Pharma and Babraham Institute Enterprises Ltd.
Mark has 25+ years’ experience in the discovery of novel treatments for diseases of the nervous system. Following an early career at Pfizer, he founded Cambridge Drug Discovery and served as CEO, growing the company to exit to BioFocus for £28m. Over the past 15 years, Mark has helped to raise over £150m for various early-stage biotechnology companies and has served on the boards of 16 private and public companies.
Denise has over 25 years experience in the biopharmaceutical industry, in R&D management and as a VC. In 1999 she joined Nomura and became MD after heading the life science investment team investing globally in biotech companies. She led the Phase4 Partners MBO from Nomura in 2010. Denise has served on many US and European private and public boards, including Idenix (until acquired by Merck for $3.85bn).
Fiona was Founder & CSO of Heptares,a clinical-stage company creating novel medicines targeting G protein-coupled receptors (GPCRs), a superfamily of receptors linked to a wide range of human diseases. Heptares was acquired by Japanese biopharmaceutical giant Sosei Group in a $400m deal in 2015.
Melanie was Founding CEO and now NED of NightstaRx, a Syncona backed private biopharmaceutical company specialised in bringing sight improving treatments to patients with retinal dystrophies. Melanie is currently CSO of BTG plc, a fast growing Interventional Medicine company on the international stage with its HQ in London.